These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7698539)

  • 1. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
    Gregor M
    Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of somatostatin analog in management of carcinoid syndrome.
    Vinik A; Moattari AR
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
    Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
    Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoid crisis after biopsy of a bronchial carcinoid.
    Karmy-Jones R; Vallières E
    Ann Thorac Surg; 1993 Dec; 56(6):1403-5. PubMed ID: 8267450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current treatment of carcinoid tumor].
    Elizalde I; Borda F
    Gastroenterol Hepatol; 2002 Oct; 25(8):508-13. PubMed ID: 12361534
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
    Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
    Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoid tumors.
    Boushey RP; Dackiw AP
    Curr Treat Options Oncol; 2002 Aug; 3(4):319-26. PubMed ID: 12074768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management.
    Vinik AI; Thompson N; Eckhauser F; Moattari AR
    Acta Oncol; 1989; 28(3):389-402. PubMed ID: 2663049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.
    Kvols LK
    Am J Med; 1986 Dec; 81(6B):49-55. PubMed ID: 2432781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.